• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Connect Biopharma Holdings Ltd ADR (NQ: CNTB )

    1.350 +0.030 (+2.27%)
    Streaming Delayed Price Updated: 3:59 PM EDT, Jul 24, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 23,765
    Open 1.350
    Bid (Size) 1.320 (20)
    Ask (Size) 1.390 (3)
    Prev. Close 1.320
    Today's Range 1.300 - 1.365
    52wk Range 0.5347 - 2.840
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga

    Performance

    YTD
    +9.76%
    +9.76%
    1 Month
    N/A
    N/A
    3 Month
    -1.46%
    -1.46%
    6 Month
    +7.14%
    +7.14%
    1 Year
    +31.07%
    +31.07%

    More News

    Read More
    Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    Connect Biopharma Announces New Leadership and Chair of the Board of Directors
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Week in Review: SystImmune Out-Licenses Global Rights for ADC to BMS in $8.4 Billion Deal
    Via Talk Markets
    Why Icosavax Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Via InvestorPlace
    Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023
    From Connect Biopharma Holdings Limited
    Via GlobeNewswire
    Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
    Via Newsfile
    Week In Review: BeiGene Signs $1.3 Billion Deal For Preclinical CDK2 Inhibitor From Boston’s Ensem
    Via Talk Markets
    Why Urban Outfitters Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Why Guess? Shares Are Trading Lower By Around 15%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.